Literature DB >> 32552873

Neutrophil-lymphocyte ratio associated with poor prognosis in oral cancer: a retrospective study.

Takumi Hasegawa1, Tomoya Iga2, Daisuke Takeda2, Rika Amano2, Izumi Saito2, Yasumasa Kakei2, Junya Kusumoto2, Akira Kimoto2, Akiko Sakakibara2, Masaya Akashi2.   

Abstract

BACKGROUND: Prognostic biomarkers provide essential information about a patient's overall outcome. However, existing biomarkers are limited in terms of either sample collection, such as requiring tissue specimens, or the process, such as prolonged time for analysis. In view of the need for convenient and non-invasive prognostic biomarkers for oral cancer, we aimed to investigate the prognostic values of neutrophil-to-lymphocyte ratio, lymphocyte-to-monocyte ratio, and platelet-to-lymphocyte ratio in patient survival. We also aimed to explore the associations of these ratios with the clinicopathologic characteristics of Japanese oral squamous cell carcinoma patients.
METHODS: This study was a non-randomized retrospective cohort study in a tertiary referral center. We included 433 patients (246 men, 187 women) who underwent radical surgery for oral cancers between January 2001 and December 2013. We evaluated various risk factors for poor prognosis including neutrophil-to-lymphocyte ratio, lymphocyte-to-monocyte ratio, and platelet-to-lymphocyte ratio with univariate and multivariate analyses. The disease-specific survival and overall survival rates of patients were compared among the factors and biomarkers.
RESULTS: In multivariable Cox proportional hazards analysis, high neutrophil-to-lymphocyte ratio (hazard ratio 2.87, 95% confidence interval 1.59-5.19, P <  0.001), moderately or poorly differentiated histology (hazard ratio 2.37, 95% confidence interval 1.32-4.25, P <  0.001), and extranodal extension (hazard ratio 1.95, 95% confidence interval 1.13-3.35, P = 0.016) were independent predictors of disease-specific survival. High neutrophil-to-lymphocyte ratio (hazard ratio 2.30, 95% confidence interval 1.42-3.72, P <  0.001), moderately or poorly differentiated (hazard ratio 1.72, 95% confidence interval 1.07-2.76, P = 0.025), and extranodal extension (hazard ratio 1.79, 95% confidence interval 1.13-2.84, P = 0.013) were independent predictors of overall survival.
CONCLUSIONS: Neutrophil-to-lymphocyte ratio might be a potential independent prognostic factor in Japanese oral squamous cell carcinoma patients.

Entities:  

Keywords:  Disease-specific survival; Lymphocyte-to-monocyte ratio; Neutrophil-to-lymphocyte ratio; Oral squamous cell carcinoma; Overall survival; Platelet-to-lymphocyte ratio

Year:  2020        PMID: 32552873      PMCID: PMC7302163          DOI: 10.1186/s12885-020-07063-1

Source DB:  PubMed          Journal:  BMC Cancer        ISSN: 1471-2407            Impact factor:   4.430


Background

Oral squamous cell carcinoma (OSCC) is the most common tumor of the head and neck region, and occurs predominantly in the oral cavity (90%) [1]. There have been recent improvements in the treatment of advanced OSCC. However, the survival of oral cancer patients has not dramatically improved [2]. Prognostic biomarkers are important for treatment because they provide essential information about the patients’ overall outcome. However, molecular biomarkers that need tissue specimens for analysis impose burden on patients, as it requires an invasive approach for sample collection. The analysis time for tissue biomarkers is also long. Therefore, there is an urgent need for convenient and non-invasive prognostic biomarkers for oral cancer. It is well known that cancer has a close relationship with inflammation [3]. Inflammatory responses cause tumor progression such as initiation, progression, and metastasis [4]. The peripheral blood cell counts of the lymphocytes, monocytes, neutrophils, and platelets are reported to be associated with prognosis in several cancers [5-7]. These values can be activated by oxidative stress, chemokines, and cytokines during cancer initiation and progression [8, 9]. One report suggested that leukocytes work differently in patients with cancer and those without [10]. The neutrophil-to-lymphocyte ratio (NLR), lymphocyte-to-monocyte ratio (LMR), and platelet-to-lymphocyte ratio (PLR) are important hematological biomarkers and have been reported to be significant prognostic markers of head and neck cancer [11-13]. However, the results are controversial. Furthermore, few studies have quantitatively analyzed the usefulness of NLR, LMR, and PLR in predicting the prognosis in a small number of Japanese OSCC patients [14, 15]. In this study, we retrospectively investigated the prognostic values of NLR, LMR, and PLR in patient survival and their associations with the clinicopathologic characteristics of Japanese OSCC patients.

Methods

This was a non-randomized retrospective cohort study. This study was approved by the institutional review board of the Kobe University Graduate School of Medicine and by the institutional review boards of the participating hospitals (Authorization number: 170086). The patient group included 433 patients (246 men, 187 women) who underwent radical surgery for OSCC between January 2001 and December 2013 at the Department of Oral and Maxillofacial Surgery, Kobe University Hospital. The mean patient age was 66.3 ± 13.5 years (range: 22–98 years). The inclusion criteria were as follows: a histological diagnosis of OSCC and the presence of a previously untreated tumor scheduled for radical surgery at initial visit. Patients with factors that could influence the NLR, LMR, and PLR such as concurrent infections, chronic inflammatory diseases, chronic hematologic diseases, and recent treatment with steroids or immunosuppressive agents were also excluded. The data assessed for each patient included the sex, age, smoking history, alcohol consumption, performance status (PS), subsite, clinical T classification (Union Internationale Contre le Cancer/American Joint Committee on Cancer [UICC/AJCC] staging system 7th edition), clinical N classification, histological grade (well differentiated, moderately differentiated, or poorly differentiated), surgical margins, number of pathologically metastatic lymph nodes, presence of pathologic extra nodal extension (ENE), and treatment outcome. The endpoints evaluated were; the disease-specific survival (DSS) rates as the primary outcome and the overall survival (OS) rates as the secondly outcome. Survival times were calculated from the date of surgery. The peripheral NLR was calculated as the ratio of the absolute peripheral neutrophil to lymphocyte count; the peripheral LMR was calculated as the ratio of the absolute peripheral lymphocyte to monocyte count, and the peripheral PLR was calculated as the ratio of the absolute peripheral platelet to lymphocyte count. The discriminatory ability of NLR, LMR, and PLR as possible indicators of DSS was evaluated with a receiver operating characteristic (ROC) curve. This ROC curve was used to determine the cutoff values for clinical tests. The area under the resulting curve (AUC) measured the accuracy of the discrimination, ranging from 0.5 to 1. The cutoff value was chosen to minimize the number of false-positive and false-negative results. The patients were divided into two groups (the low group and high group) based on NLR, LMR, and PLR values. The DSS and OS rates of patients were compared among the patient characteristics including the NLR, LMR, and PLR. The data were introduced into a multivariate Cox proportional hazard model in which patients were divided by age (≤ 64 years vs. ≥ 65 years), PS (0 vs. 1, 2, or 3), subsite (tongue vs. others), T stage (1 or 2 vs. 3 or 4), N stage (0 vs. others), histological grade (well vs. moderately or poorly differentiated), surgical margins (negative vs. close or positive), and number of pathologically metastatic lymph nodes (0 or 1 vs. ≥2).

Statistical analysis

SPSS 22.0 (SPSS, Chicago, IL) and Ekuseru-Toukei 2012 (Social Survey Research Information Co., Ltd., Tokyo, Japan) were used for the statistical analyses. The association of each variable with the NLR, LMR and PLR were analyzed by the Mann-Whitney U nonparametric test for ordinal variables and the Fisher’s exact test or the Chi-squared test for categorical variables. Cumulative DSS and OS were calculated using the Kaplan–Meier product limit method. Significance among the curves was determined using the log-rank test. Probabilities of less than 0.05 were accepted as significant. All of the variables associated with the DSS or OS were introduced into multivariate Cox proportional hazard models. Hazard ratio (HR) and 95% confidence intervals (CIs) were also calculated.

Results

The mean follow-up time among the 433 patients was 59.1 (range, 1–179) months. During the follow-up period, the 5-year OS rate and DSS were 77.3 and 84.1%. The tongue was the most common site [n = 211 (48.7%)]. The mean NLR, LMR, and PLR were 2.50 ± 1.73, 5.51 ± 3.47, and 143.4 ± 71.7, respectively. The optimal cutoff values of NLR, LMR, and PLR were 2.22, 4.35, and 134.3, respectively. The AUC of the NLR ROC curve was 0.72 (sensitivity, 0.71; specificity, 0.58). The AUC of the LMR ROC curve was 0.66 (sensitivity, 0.62; specificity, 0.62). The AUC of the PLR ROC curve was 0.60 (sensitivity, 0.56; specificity, 0.59). There were significant differences between the two NLR groups in the presence of pathological multiple lymph node metastases (P = 0.044) in the univariate analysis (Table 1). There were no significant differences in other factors (Table 1). There were significant differences between the patients with high PS (P = 0.002), subsite other than the tongue (P = 0.015), high T stage (P = 0.003), and high N stage (P = 0.007) in the patients with low LMR in the univariate analysis (Table 2). There were no significant differences in other factors (Table 2). There were significant differences between the females (P <  0.001) and no smoking history (P = 0.002) in the high PLR group in the univariate analysis (Table 3). There were no significant differences in other factors (Table 3).
Table 1

Characteristics of patients according to NLR

VariablesNLRP value
Low, n (%)High, n (%)
Number of patients233 (53.8)200 (46.2)
Sex
 Male142 (60.9)104 (52.0)0.065 *
 Female91 (39.1)96 (48.0)
Age
 Range (Years)27–9822–92
 Mean ± SD65.7 ± 13.067.0 ± 14.00.170 **
  ≥ 6495 (40.8)78 (39.0)0.768 *
  ≤ 65138 (59.2)122 (61.0)
Smoking history
 No112 (48.1)107 (53.5)0.179 *
 Yes47 (20.2)22 (11.0)
Unknown74 (31.8)71 (35.5)
Alcohol consumption
 No81 (34.8)71 (35.5)0.472 *
 Yes76 (32.6)55 (27.5)
 Unknown76 (32.6)74 (37.0)
Performance status
 0131 (56.2)96 (48.0)0.121 *
  ≥ 1101 (43.4)101 (50.5)
 unknown1 (0.4)3 (1.5)
Subsite
 Tongue116 (49.8)95 (47.5)0.700 *
 Other117 (50.2)105 (52.5)
T classification
 1, 2167 (71.7)134 (67.0)0.297 *
 3, 4a/b66 (28.3)66 (33.0)
N classification
 0168 (72.1)128 (64.0)0.078 *
 Others65 (27.9)72 (36.0)
Pathological status
 Pathological extranodal extensions
  ENE -44 (57.9)45 (54.9)0.750 *
  ENE +32 (42.1)37 (45.1)
 Number of pathological lymph node metastases
 0, 1101 (69.2)72 (57.1)0.044 *
  ≥ 245 (30.8)54 (42.9)
Surgical margins
 Negative180 (77.3)147 (73.5)0.358 *
 Involved margins49 (21.0)50 (25.0)
 Unknown4 (1.7)3 (1.5)
Histological differentiation
 Well differentiated135 (57.9)126 (63.0)0.372 *
 Moderately or poorly differentiated95 (40.8)73 (36.5)
 Unknown3 (1.3)1 (0.5)

ENE Extranodal extension; NLR Neutrophil-lymphocyte ratio

*: Fisher’s exact test **: Mann–Whitney U test

Table 2

Characteristics of patients according to LMR

VariablesLMRP value
Low, n (%)High, n (%)
Number of patients180 (41.6)253 (58.4)
Sex
 Male112 (62.2)134 (53.0)0.062 *
 Female68 (37.8)119 (47.0)
Age
 Range (Years)22–9223–98
 Mean ± SD67.8 ± 12.965.3 ± 13.80.057 **
  ≥ 6466 (36.7)107 (42.3)0.273 *
  ≤ 65114 (63.3)146 (57.7)
Smoking history
 No94 (52.2)125 (49.4)0.680 *
 Yes32 (17.8)37 (14.6)
 Unknown54 (30.0)91 (36.0)
Alcohol consumption
 No63 (35.0)89 (35.2)0.282 *
 Yes63 (35.0)68 (26.9)
 Unknown54 (30.0)96 (37.9)
Performance status
 078 (43.3)149 (58.9)0.002 *
  ≥ 1100 (55.6)102 (40.3)
 Unknown2 (1.1)2 (0.8)
Subsite
 Tongue75 (41.7)136 (53.8)0.015 *
 Other105 (58.3)117 (46.2)
T classification
 1, 2111 (61.7)190 (75.1)0.003 *
 3, 4a/b69 (38.3)63 (24.9)
N classification
 0110 (61.1)186 (73.5)0.007 *
 Others70 (38.9)67 (26.5)
Pathological status
 Pathological extranodal extension
  ENE -41 (52.6)48 (60.0)0.423 *
  ENE +37 (47.4)32 (40.0)
 Number of pathological lymph node metastases
  0, 174 (58.3)99 (68.3)0.101 *
   ≥ 253 (41.7)46 (31.7)
 Surgical margins
  Negative133 (73.9)194 (76.7)0.417 *
  Involved margins45 (25.0)54 (21.3)
  Unknown2 (1.1)5 (2.0)
 Histological differentiation
  Well differentiated107 (59.4)154 (60.9)0.736 *
  Moderately or poorly differentiated72 (40.0)96 (37.9)
  Unknown1 (0.6)3 (1.2)

ENE Extranodal extension; LMR Lymphocyte-to-monocyte ratio

*: Fisher’s exact test **: Mann–Whitney U test

Table 3

Characteristics of patients according to PLR

VariablesPLRP value
Low, n (%)High, n (%)
Number of patients240 (55.4)193 (44.6)
Sex
 Male156 (65.0)90 (46.6)<  0.001 *
 Female84 (35.0)103 (53.4)
Age
 Range (Years)27–9822–92
 Mean ± SD66.1 ± 12.766.6 ± 14.40.253 **
  ≥ 64100 (41.7)73 (37.8)0.431 *
  ≤ 65140 (58.3)120 (62.2)
Smoking history
 No115 (47.9)104 (53.9)0.002 *
 Yes51 (21.3)18 (9.3)
 Unknown74 (30.8)71 (36.8)
Alcohol consumption
 No84 (35.0)68 (35.2)0.473 *
 Yes78 (32.5)53 (27.5)
 Unknown78 (32.5)72 (37.3)
Performance status
 0135 (56.3)92 (47.7)0.081 *
  ≥ 1103 (38.8)99 (41.3)
 Unknown2 (0.8)2 (1.0)
Subsite
 Tongue126 (52.5)85 (44.0)0.083 *
 Other114 (47.5)108 (56.0)
T classification
 1, 2176 (73.3)125 (64.8)0.059 *
 3, 4a/b64 (26.7)68 (35.2)
N classification
 0168 (70.0)128 (66.3)0.467 *
 Others72 (30.0)65 (33.7)
Pathological status
 Pathological extranodal extension
  ENE -49 (57.6)40 (54.8)0.750 *
  ENE +36 (42.4)33 (45.2)
 Number of pathological lymph node metastases
  0, 194 (63.9)79 (63.2)0.900 *
   ≥ 253 (36.1)46 (36.8)
 Surgical margins
  Negative184 (76.7)143 (74.1)0.421 *
  Involved margins51 (21.3)48 (24.9)
  Unknown5 (2.1)2 (1.0)
 Histological differentiation
  Well differentiated142 (59.2)119 (61.7)0.691 *
  Moderately or poorly differentiated95 (39.6)73 (37.8)
  Unknown3 (1.3)1 (0.5)

ENE Extranodal extension; PLR Platelet-to-lymphocyte ratio

*: Fisher’s exact test **: Mann–Whitney U test

Characteristics of patients according to NLR ENE Extranodal extension; NLR Neutrophil-lymphocyte ratio *: Fisher’s exact test **: Mann–Whitney U test Characteristics of patients according to LMR ENE Extranodal extension; LMR Lymphocyte-to-monocyte ratio *: Fisher’s exact test **: Mann–Whitney U test Characteristics of patients according to PLR ENE Extranodal extension; PLR Platelet-to-lymphocyte ratio *: Fisher’s exact test **: Mann–Whitney U test Univariate analysis showed that high T stage (P <  0.001), high N stage (P <  0.001), high NLR (P <  0.001), low LMR (P <  0.001), high PLR (P = 0.044), ENE (P = 0.004), pathological multiple lymph node metastases (P <  0.001), involved margins (P = 0.030), and moderately or poorly differentiated histology (P <  0.001) were associated with poor 5-year DSS (Table 4). Univariate analysis showed that high PS (P = 0.025), high T stage (P <  0.001), high N stage (P <  0.001), high NLR (P <  0.001), low LMR (P = 0.001), ENE (P = 0.012), pathological multiple lymph node metastases (P <  0.001), involved margins (P = 0.043), and moderately or poorly differentiated histology (P = 0.001) were associated with poor 5-year OS (Table 4).
Table 4

Characteristics of patients according to DSS and OS

Variablesn (%)5-year DSS (%)P value5-year OS (%)P value
Sex
 Male246 (56.8)83.10.684 *74.60.126 *
 Female187 (43.2)84.880.5
Age
 Range (Years)22–98
 Mean ± SD66.3 ± 13.5
  ≥ 64173 (40.0)79.90.120 *73.70.608 *
  ≤ 65260 (60.0)86.679.6
Smoking history
 No219 (50.6)88.20.548 *82.50.179 *
 Yes69 (15.9)85.376.7
 Unknown145 (33.5)
Alcohol consumption
 No152 (35.1)83.90.105 *77.30.391 *
 Yes131 (30.3)91.284.6
 Unknown150 (34.6)
Performance status
 0227 (52.4)85.20.274 *79.60.025 *
  ≥ 1202 (46.7)81.974.3
 unknown4 (0.9)
Subsite
 Tongue211 (48.7)85.40.311 *80.20.083 *
 Other222 (51.3)82.273.9
T classification
 1, 2301 (69.5)88.5<  0.001 *83.1<  0.001 *
 3, 4a/b132 (30.5)72.262.4
N classification
 0296 (68.4)91.6<  0.001 *85.6<  0.001 *
 Others137 (31.6)66.458.5
NLR
 Low (2.22 <)233 (53.8)91.4<  0.001 *84.6< 0.001 *
 High (2.22 ≥)200 (46.2)75.568.8
LMR
 Low (4.35 <)253 (58.4)76.3< 0.001 *70.00.001 *
 High (4.35 ≥)180 (41.6)89.182.1
PLR
 Low (134.3 <)240 (55.4)86.60.044 *78.40.232 *
 High (134.3 ≥)193 (44.6)80.675.6
Pathological status
 Pathological extra nodal metastasis
  ENE -89 (56.3)72.80.004 *63.70.012 *
  ENE +69 (43.7)50.742.4
 Number of pathological lymph node metastases
  0, 1173 (63.6)84.7< 0.001 *78.1< 0.001 *
   ≥ 299 (36.4)60.850.1
 Surgical margins
  Negative314 (72.5)85.50.030 *78.70.043 *
  Involved margins112 (25.9)79.172.1
  unknown7 (1.6)
 Histological differentiation
  Well differentiated261 (60.3)91.5< 0.001 *83.30.001 *
  Moderately or poorly differentiated168 (38.8)71.767.0
  unknown4 (0.9)

DSS Disease- specific survival; ENE Extranodal extension; LMR Lymphocyte-to-monocyte ratio; NLR Neutrophil-to-lymphocyte ratio; OS Overall survival; PLR Platelet-to-lymphocyte ratio

*: Log-rank test

Characteristics of patients according to DSS and OS DSS Disease- specific survival; ENE Extranodal extension; LMR Lymphocyte-to-monocyte ratio; NLR Neutrophil-to-lymphocyte ratio; OS Overall survival; PLR Platelet-to-lymphocyte ratio *: Log-rank test The 5-year DSS rates of patients with high and low NLR were 75.5 and 91.4%, respectively (Fig. 1). The 5-year OS rates of patients with high and low NLR were 68.8 and 84.6%, respectively. The 5-year DSS rates of patients with high and low LMR were 89.1 and 76.3%, respectively (Fig. 2). The 5-year OS rates of patients with high and low LMR were 82.1 and 70.0%, respectively. The 5-year DSS rates of patients with high and low PLR were 80.6 and 86.6%, respectively (Fig. 3). The 5-year OS rates of patients with high and low PLR were 75.6 and 78.4%, respectively.
Fig. 1

Cumulative disease-specific survival (DSS) rates in patients with high and low neutrophil-to-lymphocyte ratio (NLR). The 5-year DSS rates of patients with high and low NLR were 75.5 and 91.4%, respectively

Fig. 2

Cumulative disease-specific survival (DSS) rates in patients with high and low lymphocyte-to-monocyte ratio (LMR). The 5-year DSS rates of patients with high and low LMR were 89.1 and 76.3%, respectively

Fig. 3

Cumulative disease-specific survival (DSS) rates in patients with high and low platelet-to-lymphocyte ratio (PLR). The 5-year DSS rates of patients with high and low PLR were 80.6 and 86.6%, respectively

Cumulative disease-specific survival (DSS) rates in patients with high and low neutrophil-to-lymphocyte ratio (NLR). The 5-year DSS rates of patients with high and low NLR were 75.5 and 91.4%, respectively Cumulative disease-specific survival (DSS) rates in patients with high and low lymphocyte-to-monocyte ratio (LMR). The 5-year DSS rates of patients with high and low LMR were 89.1 and 76.3%, respectively Cumulative disease-specific survival (DSS) rates in patients with high and low platelet-to-lymphocyte ratio (PLR). The 5-year DSS rates of patients with high and low PLR were 80.6 and 86.6%, respectively In multivariable Cox proportional hazard analysis, high NLR (Hazard ratio, HR 2.87; 95% confidence interval, CI 1.59–5.19; P <  0.001), moderately or poorly differentiated histology (HR 2.37, 95% CI 1.32–4.25, P <  0.001), and ENE (HR 1.95, 95% CI 1.13–3.35, P = 0.016) were independent predictors of DSS (Table 5). Also, high NLR (HR 2.30, 95% CI 1.42–3.72, P < 0.001), moderately or poorly differentiated (HR 1.72, 95% CI 1.07–2.76, P = 0.025), and ENE (HR 1.79, 95% CI 1.13–2.84, P = 0.013) were independent predictors of OS (Table 6).
Table 5

Results of multivariate Cox proportional hazards analysis of predictors of disease-specific survival

VariableP valueHazards ratio95% CI
LowerUpper
High NLR (2.22 ≥)< 0.0012.871.595.19
Moderately or poorly differentiated histology< 0.0012.371.324.25
Extranodal extension0.0161.951.133.35

CI Confidence interval; NLR Neutrophil-to-lymphocyte ratio

Table 6

Results of multivariate Cox proportional hazards analysis of predictors of overall survival (OS)

VariableP valueHazards ratio95% CI
LowerUpper
High NLR (2.22 ≥)< 0.0012.301.423.72
Moderately or poorly differentiated histology0.0251.721.072.76
Extra nodal extension0.0131.791.132.84

CI Confidence interval; NLR Neutrophil-to-lymphocyte ratio

Results of multivariate Cox proportional hazards analysis of predictors of disease-specific survival CI Confidence interval; NLR Neutrophil-to-lymphocyte ratio Results of multivariate Cox proportional hazards analysis of predictors of overall survival (OS) CI Confidence interval; NLR Neutrophil-to-lymphocyte ratio

Discussion

We successfully investigated the prognostic values of NLR, LMR, and PLR in patient survival and their associations with the clinicopathologic characteristics of Japanese OSCC patients. In particular, high NLR was associated with poor prognosis. The association between NLR and prognostic factors have been reported in various cancers [6, 16]. The measurement of NLR is very accessible and affordable because blood sampling is used. Therefore, NLR could be used as a simple indicator of systemic inflammatory responses in cancer patients. Neutrophils secrete matrix metalloproteinase 9 to promote carcinogenesis and tumor cell proliferation into the cancer microenvironment [17, 18]. In contrast, lymphocytes suppress tumor progression and are associated with an increased survival in various cancers [19, 20]. In this study, like other reports, a high NLR was associated with poor DSS and OS [15, 21, 22]. In multivariable Cox proportional hazards analysis, high NLR (HR 2.87) was an independent predictor of poor prognosis. The cutoff value of NLR ranged from 1.77 to 5 [23]. In Japan, Nakashima et al. and Sano et al. reported that the cutoff values were 2.4 and 2.36, respectively [15, 24]. In this study, the cutoff value was 2.22, like in these reports. The association between NLR and clinicopathological factors such as lymph node metastasis, T stage, differentiation, and perineural invasion was reported [23]. In this study, there were significant differences in the presence of pathological multiple lymph node metastases in the patients with high NLR like in several reports [14, 21, 22]. Therefore, NLR may be useful in predicting multiple lymph node metastasis. The association between LMR and prognostic factors were reported in head and neck cancers [12]. Ong et al. reported that low pretreatment LMR indicated poor survival in patients with early tongue cancer [24]. In this study, low LMR was associated with poor DSS and OS like their report. A low LMR may mean a relative decrease in lymphocytes and increase in monocytes. The decreasing lymphocytes may be related to high NLR or high PLR. Tsai et al. reported that a higher pretreatment count of circulating monocytes was independently associated with poor prognosis in patients with oral cancer [25]. Chronic inflammation including cancer increases the monocyte count by the secretion of various cytokines such as TNF-α, IL-1, and IL-6 [26]. Generally, the monocytes differentiate into macrophages. Pollard et al. reported that an increased number of tumor-associated macrophages was associated with poor prognosis in cancers [27]. The cutoff value of LMR ranged from 2.35 to 5.22 [12, 24]. In this study, the cutoff value was 4.35 like these reports. The relationship between PLR and poor prognosis is controversial. Several investigators suggested that a high PLR indicated poor prognosis in patients with head and neck SCC [13, 24]. In this study, a high PLR was associated with poor DSS. In contrast, Yu et al. indicated that preoperative PLR was not associated with survival or relapse in oral, pharyngeal, and lip cancer [28]. There are several possibilities, although the exact mechanism of the association between a high PLR and poor prognosis is not clear. Platelets can promote tumor progression by increasing angiogenesis through secretion of vascular endothelial growth factor, and invasion, and metastasis through epithelial-mesenchymal transition [13, 29–32]. The cutoff value of PLR ranged from 82 to 150 [13]. In patients with oral cancer, Chen et al. and Ong et al. reported that the cutoff values were 135 and 129 [24, 33]. In this study, the cutoff value was 134 like those reports. In multivariable Cox proportional hazards analysis of this study, a low LMR and high PLR were not independent predictors of poor prognosis. Therefore, unlike NLR and other factors, LMR and PLR may not be useful in Japanese OSCC patients. This study had several limitations. First, this study was conducted in Japanese OSCC patients. Each cutoff value was different from other studies. Therefore, it may be clinically difficult to be used in patients of other countries. Second, the present study was retrospective and nonrandomized. Therefore, bias could not be completely excluded, although multivariate analysis was performed to decrease the effect of confounding factors as much as possible. Future research should involve a large-scale prospective cohort study to evaluate predictors of prognosis and NLR, LMR, or PLR.

Conclusions

High NLR, moderately or poorly differentiated histology, and ENE were independent predictors of DSS and OS. In particular, high NLR was associated with poor prognosis. The NLR might be a potential independent prognostic factor in Japanese OSCC patients.
  33 in total

Review 1.  Immunity, inflammation, and cancer.

Authors:  Sergei I Grivennikov; Florian R Greten; Michael Karin
Journal:  Cell       Date:  2010-03-19       Impact factor: 41.582

2.  Low Pretreatment Lymphocyte-Monocyte Ratio and High Platelet-Lymphocyte Ratio Indicate Poor Cancer Outcome in Early Tongue Cancer.

Authors:  Hui Shan Ong; Sandhya Gokavarapu; Li Zhen Wang; Zhen Tian; Chen Ping Zhang
Journal:  J Oral Maxillofac Surg       Date:  2016-12-26       Impact factor: 1.895

3.  Preoperative neutrophil lymphocyte ratio but not platelet lymphocyte ratio predicts survival and early relapse in patients with oral, pharyngeal, and lip cancer.

Authors:  Wenjie Yu; Yu Dou; Ketao Wang; Yanguo Liu; Jintang Sun; Han Gao; Shaohua Liu; Fengcai Wei; Daoying Yuan; Xiaobin Song; Xun Qu
Journal:  Head Neck       Date:  2019-01-11       Impact factor: 3.147

4.  Neutrophil-to-lymphocyte ratio in head and neck cancer prognosis: A systematic review and meta-analysis.

Authors:  Marco A Mascarella; Erin Mannard; Sabrina Daniela Silva; Anthony Zeitouni
Journal:  Head Neck       Date:  2018-01-22       Impact factor: 3.147

Review 5.  Prognostic biomarkers in oral squamous cell carcinoma: A systematic review.

Authors:  César Rivera; Ana Karina Oliveira; Rute Alves Pereira Costa; Tatiane De Rossi; Adriana Franco Paes Leme
Journal:  Oral Oncol       Date:  2017-07-12       Impact factor: 5.337

6.  Paracrine regulation of vascular endothelial growth factor--a expression during macrophage-melanoma cell interaction: role of monocyte chemotactic protein-1 and macrophage colony-stimulating factor.

Authors:  Michelle L Varney; Kimberlee J Olsen; R Lee Mosley; Rakesh K Singh
Journal:  J Interferon Cytokine Res       Date:  2005-11       Impact factor: 2.607

7.  Prognostic Value of Pretreatment Lymphocyte-to-Monocyte Ratio in Non-Small Cell Lung Cancer: A Meta-Analysis.

Authors:  Yan Wang; Dong Huang; Wen-Ying Xu; Yan-Wen Wang; Guo-Wei Che
Journal:  Oncol Res Treat       Date:  2019-07-18       Impact factor: 2.825

Review 8.  Platelets and angiogenesis in malignancy.

Authors:  Ewa Sierko; Marek Z Wojtukiewicz
Journal:  Semin Thromb Hemost       Date:  2004-02       Impact factor: 4.180

9.  Direct signaling between platelets and cancer cells induces an epithelial-mesenchymal-like transition and promotes metastasis.

Authors:  Myriam Labelle; Shahinoor Begum; Richard O Hynes
Journal:  Cancer Cell       Date:  2011-11-15       Impact factor: 31.743

10.  Pre-treatment neutrophil to lymphocyte ratio predicts the chemoradiotherapy outcome and survival in patients with oral squamous cell carcinoma: a retrospective study.

Authors:  Hikaru Nakashima; Yuichiro Matsuoka; Ryoji Yoshida; Masashi Nagata; Akiyuki Hirosue; Kenta Kawahara; Junki Sakata; Hidetaka Arita; Akimitsu Hiraki; Hideki Nakayama
Journal:  BMC Cancer       Date:  2016-01-26       Impact factor: 4.430

View more
  6 in total

Review 1.  Pre-treatment neutrophil-to-lymphocyte ratio is an independent prognostic factor in head and neck squamous cell carcinoma: Meta-analysis and trial sequential analysis.

Authors:  Pierluigi Mariani; Diana Russo; Marco Maisto; Giuseppe Troiano; Vito Carlo Alberto Caponio; Marco Annunziata; Luigi Laino
Journal:  J Oral Pathol Med       Date:  2021-12-09       Impact factor: 3.539

2.  Clinical Significance of Preoperative Inflammatory Markers in Prediction of Prognosis in Node-Negative Colon Cancer: Correlation between Neutrophil-to-Lymphocyte Ratio and Poorly Differentiated Clusters.

Authors:  Giulia Turri; Valeria Barresi; Alessandro Valdegamberi; Gabriele Gecchele; Cristian Conti; Serena Ammendola; Alfredo Guglielmi; Aldo Scarpa; Corrado Pedrazzani
Journal:  Biomedicines       Date:  2021-01-19

3.  Survival Outcomes in Oral Tongue Cancer: A Mono-Institutional Experience Focusing on Age.

Authors:  Mohssen Ansarin; Rita De Berardinis; Federica Corso; Gioacchino Giugliano; Roberto Bruschini; Luigi De Benedetto; Stefano Zorzi; Fausto Maffini; Fabio Sovardi; Carolina Pigni; Donatella Scaglione; Daniela Alterio; Maria Cossu Rocca; Susanna Chiocca; Sara Gandini; Marta Tagliabue
Journal:  Front Oncol       Date:  2021-04-12       Impact factor: 6.244

4.  Prognostic Role of High-Sensitivity Modified Glasgow Prognostic Score for Patients With Operated Oral Cavity Cancer: A Retrospective Study.

Authors:  Yao-Te Tsai; Ku-Hao Fang; Cheng-Ming Hsu; Chia-Hsuan Lai; Sheng-Wei Chang; Ethan I Huang; Ming-Shao Tsai; Geng-He Chang; Chih-Wei Luan
Journal:  Front Oncol       Date:  2022-02-15       Impact factor: 6.244

5.  Utility of prognostic nutritional index and systemic immune-inflammation index in oral cancer treatment.

Authors:  Kosei Kubota; Ryohei Ito; Norihiko Narita; Yusuke Tanaka; Ken Furudate; Natsumi Akiyama; Chuang Hao Chih; Shotaro Komatsu; Wataru Kobayashi
Journal:  BMC Cancer       Date:  2022-04-07       Impact factor: 4.430

6.  Prognostic Role of Systemic Inflammatory Markers in Patients Undergoing Surgical Resection for Oral Squamous Cell Carcinoma.

Authors:  Uiju Cho; Yeoun-Eun Sung; Min-Sik Kim; Youn-Soo Lee
Journal:  Biomedicines       Date:  2022-05-29
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.